Clarivate Appoints New Director, J.P. Garnier

Ticker: CLVT · Form: 8-K · Filed: 2025-02-28T00:00:00.000Z

Sentiment: neutral

Topics: board-appointment, governance

Related Tickers: CLVT

TL;DR

Clarivate adds J.P. Garnier, ex-GSK CEO, to its board.

AI Summary

Clarivate Plc announced on February 28, 2025, that its Board of Directors has appointed Dr. J.P. Garnier as a Class II Director, effective February 25, 2025. Dr. Garnier will serve until the company's 2027 annual general meeting and will be a member of the Audit Committee and the Nominating and Corporate Governance Committee. He previously served as CEO of GlaxoSmithKline plc.

Why It Matters

The appointment of a new director with significant industry experience can signal strategic shifts or enhanced governance for the company.

Risk Assessment

Risk Level: low — The filing is a routine corporate announcement regarding board appointments and does not involve significant financial transactions or operational changes.

Key Players & Entities

FAQ

Who has been appointed as a new director to the Clarivate Plc Board?

Dr. J.P. Garnier has been appointed as a Class II Director.

When is Dr. J.P. Garnier's appointment effective?

The appointment is effective as of February 25, 2025.

Until when will Dr. J.P. Garnier serve as a director?

Dr. Garnier will serve until the company's 2027 annual general meeting.

Which committees will Dr. J.P. Garnier be a member of?

Dr. Garnier will be a member of the Audit Committee and the Nominating and Corporate Governance Committee.

What was Dr. J.P. Garnier's previous executive role?

Dr. Garnier previously served as CEO of GlaxoSmithKline plc.

From the Filing

0001104659-25-019215.txt : 20250228 0001104659-25-019215.hdr.sgml : 20250228 20250228165038 ACCESSION NUMBER: 0001104659-25-019215 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20250225 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250228 DATE AS OF CHANGE: 20250228 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CLARIVATE PLC CENTRAL INDEX KEY: 0001764046 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMPUTER PROCESSING & DATA PREPARATION [7374] ORGANIZATION NAME: 06 Technology IRS NUMBER: 000000000 STATE OF INCORPORATION: Y9 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38911 FILM NUMBER: 25691515 BUSINESS ADDRESS: STREET 1: 4TH FLOOR, ST. PAUL'S GATE STREET 2: 22-24 NEW STREET CITY: ST. HELIER STATE: Y9 ZIP: JE14TR BUSINESS PHONE: (207) 433-4000 MAIL ADDRESS: STREET 1: 70 ST. MARY AXE CITY: LONDON STATE: X0 ZIP: EC3A 8BE FORMER COMPANY: FORMER CONFORMED NAME: CLARIVATE Plc DATE OF NAME CHANGE: 20200507 FORMER COMPANY: FORMER CONFORMED NAME: Clarivate Analytics PLC DATE OF NAME CHANGE: 20190108 8-K 1 tm257824d1_8k.htm FORM 8-K false 0001764046 00-0000000 0001764046 2025-02-25 2025-02-25 iso4217:USD xbrli:shares iso4217:USD xbrli:shares     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K   CURRENT REPORT   Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): February 28, 2025 ( February 25, 2025 )   CLARIVATE PLC   (Exact name of registrant as specified in its charter)   Jersey , Channel Islands (State or other jurisdiction of incorporation or organization)   001-38911 N/A (Commission File Number) (I.R.S Employer Identification No.)   70 St. Mary Axe London EC3A 8BE United Kingdom (Address of Principal Executive Offices)(Zip Code)   ( 44 ) 207-433-4000 (Registrant’s Telephone Number, Including Area Code)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Exchange Act:   Title of each class   Trading symbol(s)   Name of each exchange on which registered Ordinary Shares   CLVT   New York Stock Exchange   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company ¨   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨           Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.   On February 25, 2025, Michael J. Angelakis notified Clarivate Plc (the “Company”) of his decision to retire from the Board of Directors of the Company (the “Board”), effective upon the re-election of members of the Board at the Compan

View on Read The Filing